chitin

Animal productexperimental

Chitin (C8H13O5N)n ( KY-tin) is a long-chain polymer of N-acetylglucosamine, an amide derivative of glucose. Chitin is the second most abundant polysaccharide in nature (behind only cellulose); an estimated 1 billion tons of chitin are produced each year in the biosphere. It is a primary component of cell walls in fungi (especially filamentous and mushroom-forming fungi), the exoskeletons of arthropods such as crustaceans and insects, the radulae, cephalopod beaks and gladii of molluscs and in some nematodes and diatoms. It is also synthesised by at least some fish and lissamphibians. Commercially, chitin is extracted from the shells of crabs, shrimps, shellfish and lobsters, which are major by-products of the seafood industry. The structure of chitin is comparable to cellulose, forming crystalline nanofibrils or whiskers. It is functionally comparable to the protein keratin. Chitin has proved useful for several medicinal, industrial and biotechnological purposes. — Wikipedia

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2006 (NCT00443495)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • chitin
  • chitin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01508039N/AApr 30, 2011Aarhus University, CMP Therapeutics Ltd
NCT00443495Phase 1/Phase 2 (Phase 2)Oct 1, 2006CMP Therapeutics Ltd, Hammersmith Medicines Research
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CMP Therapeutics LtdFor profit2122006
Aarhus UniversityAcademic/Hospital1112011
Hammersmith Medicines ResearchFor profit1012006
3 organizations
Page 1 / 1